Verma Shailendra Prasad, Singh Bhupendra, Kushwaha Rashmi, Pavecha Punita
Clinical Hematology, King George's Medical University, Lucknow, India
Clinical Hematology, King George's Medical University, Lucknow, India.
BMJ Case Rep. 2020 Oct 30;13(10):e235687. doi: 10.1136/bcr-2020-235687.
A 61-year-old man presented to the department of clinical haematology in February 2016 with symptomatic anaemia, generalised lymphadenopathy and hepatomegaly. Routine investigations showed severe anaemia with the presence of lymphoplasmacytoid cells in the peripheral smear, and bone marrow examination with IHC and serum protein electrophoresis confirmed diagnosis of lymphoplasmacytic lymphoma. The patient received supportive transfusion therapy and combination chemotherapy. After VI cycles, the patient had a complete haematological response with marrow in remission. Maintenance rituximab was planned every 3 months for 2 years. At the time of first dose of maintenance rituximab, his haemoglobin (Hb) was 189 g/L with low normal erythropoietin level. During the last 3 years follow-up, his Hb ranged between 16.5 and 20.1 g/dL. All causes of secondary polycythaemia were ruled out. Workup for polycythAemia vera (PV), including JAK-2 and bone marrow, was not suggestive of PV. We labelled it as a case of polycythaemia due to undetermined aetiology.
一名61岁男性于2016年2月因出现症状性贫血、全身淋巴结肿大和肝肿大就诊于临床血液科。常规检查显示严重贫血,外周血涂片中有淋巴浆细胞样细胞,骨髓检查结合免疫组化和血清蛋白电泳确诊为淋巴浆细胞淋巴瘤。患者接受了支持性输血治疗和联合化疗。六个周期后,患者获得完全血液学缓解,骨髓处于缓解状态。计划每3个月给予利妥昔单抗维持治疗,持续2年。在首次给予维持性利妥昔单抗时,他的血红蛋白(Hb)为189 g/L,促红细胞生成素水平略低于正常。在过去3年的随访中,他的Hb在16.5至20.1 g/dL之间。排除了所有继发性红细胞增多症的病因。真性红细胞增多症(PV)的检查,包括JAK-2和骨髓检查,均不提示PV。我们将其标记为病因不明的红细胞增多症病例。